Carol A Hitchon1, Gilles Boire2, Boulos Haraoui3, Ed Keystone4, Janet Pope5, Shahin Jamal6, Diane Tin7, Carter Thorne7, Vivian P Bykerk8. 1. Department of Medicine, University of Manitoba, Winnipeg, Manitoba chitchon@hsc.mb.ca. 2. Division of Rheumatology, Centre hospitalier universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke. 3. Department of Medicine, Institut de Rhumatologie de Montréal, Montréal, Québec. 4. Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto. 5. Division of Rheumatology, St. Joseph's Health Care, University of Western Ontario, London, Ontario. 6. Vancouver General Hospital, University of British Columbia, Vancouver, BC. 7. Southlake Regional Health Centre, Newmarket, Ontario, Canada. 8. Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto Inflammatory Arthritis Center of Excellence, Hospital for Special Surgery, New York, NY, USA.
Abstract
OBJECTIVE: Comorbid medical conditions may influence treatment and contribute to poor outcomes in early RA. We aimed to assess the association of baseline comorbidity with outcomes in early inflammatory arthritis using data from the Canadian Early Arthritis Cohort. METHODS: Patients (n = 2090) with early inflammatory arthritis (symptom duration of < 1 year) reported comorbid medical conditions at baseline. Functional status (HAQ), detailed clinical assessments and treatment were assessed. Treatment is not protocolized but participating rheumatologists aim for remission. The influence of comorbidity on clinical outcomes was determined using multivariate models. RESULTS: At least one comorbid condition was reported by 76% of patients. Patients with comorbidity were older (mean age 56 vs 44 years, P < 0.0001) and had worse baseline function [median (interquartile range, IQR) HAQ score (0.88 (1) vs 0.75(1), P < 0.0001] compared with those without comorbidity even after controlling for age, sex and symptom duration. At 1 year, patients with baseline comorbidity were less likely to achieve remission (odds ratio, OR = 0.67; 95% CI: 0.51, 0.88, P = 0.004) and had higher HAQ [median (IQR) 0.25 (1) vs 0 (0), P < 0.0001] and pain scores [median (IQR) 2.85 (4) (out of 10) vs 1 (4), P < 0.0001] than patients without comorbidity after adjusting for age, sex, symptom duration, baseline disease activity and arthritis treatment. CONCLUSION: Comorbidity is common in early inflammatory arthritis and associated with higher disease activity, worse functional status and greater pain scores during the first year of follow-up. While the mechanisms for this association require investigation, addressing comorbidity may improve clinical outcomes in early RA.
OBJECTIVE: Comorbid medical conditions may influence treatment and contribute to poor outcomes in early RA. We aimed to assess the association of baseline comorbidity with outcomes in early inflammatory arthritis using data from the Canadian Early Arthritis Cohort. METHODS:Patients (n = 2090) with early inflammatory arthritis (symptom duration of < 1 year) reported comorbid medical conditions at baseline. Functional status (HAQ), detailed clinical assessments and treatment were assessed. Treatment is not protocolized but participating rheumatologists aim for remission. The influence of comorbidity on clinical outcomes was determined using multivariate models. RESULTS: At least one comorbid condition was reported by 76% of patients. Patients with comorbidity were older (mean age 56 vs 44 years, P < 0.0001) and had worse baseline function [median (interquartile range, IQR) HAQ score (0.88 (1) vs 0.75(1), P < 0.0001] compared with those without comorbidity even after controlling for age, sex and symptom duration. At 1 year, patients with baseline comorbidity were less likely to achieve remission (odds ratio, OR = 0.67; 95% CI: 0.51, 0.88, P = 0.004) and had higher HAQ [median (IQR) 0.25 (1) vs 0 (0), P < 0.0001] and pain scores [median (IQR) 2.85 (4) (out of 10) vs 1 (4), P < 0.0001] than patients without comorbidity after adjusting for age, sex, symptom duration, baseline disease activity and arthritis treatment. CONCLUSION: Comorbidity is common in early inflammatory arthritis and associated with higher disease activity, worse functional status and greater pain scores during the first year of follow-up. While the mechanisms for this association require investigation, addressing comorbidity may improve clinical outcomes in early RA.
Authors: Ruth Ann Marrie; Carol A Hitchon; Randy Walld; Scott B Patten; James M Bolton; Jitender Sareen; John R Walker; Alexander Singer; Lisa M Lix; Renée El-Gabalawy; Alan Katz; John D Fisk; Charles N Bernstein Journal: Arthritis Care Res (Hoboken) Date: 2018-05-21 Impact factor: 4.794
Authors: Paul Emery; Sarah Horton; Raluca Bianca Dumitru; Kamran Naraghi; Désirée van der Heijde; Richard J Wakefield; Elizabeth M A Hensor; Maya H Buch Journal: Ann Rheum Dis Date: 2020-01-29 Impact factor: 19.103
Authors: B Kuriya; O Schieir; M F Valois; J E Pope; G Boire; L Bessette; G Hazlewood; J C Thorne; D Tin; C Hitchon; S J Bartlett; E C Keystone; V P Bykerk; L Barra Journal: ACR Open Rheumatol Date: 2019-08-28
Authors: Carol A Hitchon; Lixia Zhang; Christine A Peschken; Lisa M Lix; Lesley A Graff; John D Fisk; Scott B Patten; James Bolton; Jitender Sareen; Renée El-Gabalawy; James Marriott; Charles N Bernstein; Ruth Ann Marrie Journal: Arthritis Care Res (Hoboken) Date: 2020-07-08 Impact factor: 4.794
Authors: Carol A Hitchon; Randy Walld; Christine A Peschken; Charles N Bernstein; James M Bolton; Renée El-Gabalawy; John D Fisk; Alan Katz; Lisa M Lix; James Marriott; Scott B Patten; Jitender Sareen; Alexander Singer; Ruth Ann Marrie Journal: Arthritis Care Res (Hoboken) Date: 2021-01 Impact factor: 4.794